Andres E Dulcey

age ~47

from Gaithersburg, MD

Get Report

Also known as:

Andres G Dulcey
Anres Dulcey
Dulcey Anres

Connected to:

Andres Dulcey Phones & Addresses

Gaithersburg, MD
San Mateo, CA
9731 Clagett Farm Dr, Potomac, MD 20854
4141 Spruce St, Philadelphia, PA 19104
Silver Spring, MD
Columbus, OH
4141 Spruce St APT G9, Philadelphia, PA 19104

Work

Company:

National institutes of health
Sep 2006
Position:

Irta fellow

Education

Degree:

Ph.D.
School / High School:

University of Pennsylvania
2006
Specialities:

Organic Chemistry

Industries

Research

Resumes

Irta Fellow At National Institutes Of Health

view source

Position:

IRTA Fellow at National Institutes of Health

Location:

Washington D.C. Metro Area

Industry:

Research

Work:

National Institutes of Health since Sep 2006
IRTA Fellow

Education:

University of Pennsylvania 2006
Ph.D., Organic Chemistry The Ohio State University 1999
B.S., Chemistry

Us Patents

C-Abl Tyrosine Kinase Inhibitory Compound Embodiments And Methods Of Making And Using The Same
view source
US Patent:

20210101872, Apr 8, 2021
Filed:

Mar 8, 2019
Appl. No.:

16/976012
Inventors:

- Bethesda MD, US
- Santiago, CL
Noel T. Southall - Potomac MD, US
Andres E. Dulcey - Gaithersburg MD, US
Xin Hu - Frederick MD, US
Christopher R. Dextras - Frederick MD, US
Daniel C. Talley - Baltimore MD, US
Alejandra Alvarez - Santiago, CL
Silvana Zanlungo - Santiago, CL
Rommy M. Von Bernhardi - Santiago, CL
Assignee:

The USA, as represented by the Secretary, Dept. of Health and Human Services - Bethesda MD
Pontificia Universidad Católica de Chile - Santiago
International Classification:

C07D 243/38
C07D 267/20
C07F 7/08
C07D 281/16
C07D 267/18
C07C 227/22
C07C 201/12
C07C 319/14
C07D 401/04
C07D 403/04
C07D 413/10
C07F 5/02
C07D 413/04
C07D 471/04
C07D 487/04
C07D 413/14
C07D 417/04
A61P 33/06
A61P 25/28
A61P 25/08
A61P 35/02
A61K 31/554
A61K 31/5513
A61K 31/553
Abstract:

Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as “c-Abl”). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site and inhibit its activity in various pathways. The compound embodiments also are capable of crossing the blood brain barrier and therefore are useful in inhibiting c-Abl activity as it affects pathways and/or proteins in the brain. The compound embodiments described herein are effective therapeutic agents for treating diseases involving c-Abl, such as cancers, motor neuron diseases, and neurodegenerative diseases. Also disclosed herein are embodiments of methods for making and using the c-Abl inhibitory compound embodiments.